GSA Capital Partners’s Prelude Therapeutics PRLD Stock Holding History

GSA Capital Partners’s Portfolio PRLD Stock Details PRLD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$68K	Buy	+12,672	New	+$55.2K	﹤0.01%	1648
2025 Q4	–	Sell	-75,161	Closed	-$108K	–	2000
2025 Q3	$108K	Buy	75,161 +3,783	+5%	+$3.79K	0.01%	1516
2025 Q2	$58K	Buy	+71,378	New	+$61.8K	﹤0.01%	1655
2023 Q4	–	Sell	-70,583	Closed	-$218K	–	1836
2023 Q3	$218K	Sell	70,583 -2,251	-3%	-$8.45K	0.02%	1246
2023 Q2	$328K	Buy	72,834 +25,220	+53%	+$151K	0.03%	1000
2023 Q1	$271K	Sell	47,614 -187	-0.4%	-$1.14K	0.03%	1084
2022 Q4	$289K	Sell	47,801 -6,372	-12%	-$40.8K	0.04%	952
2022 Q3	$358K	Buy	54,173 +17,547	+48%	+$118K	0.05%	816
2022 Q2	$191K	Buy	36,626 +13,425	+58%	+$68.3K	0.03%	1083
2022 Q1	$160K	Buy	+23,201	New	+$212K	0.02%	1222

Other funds holding PRLD

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

SFM

Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

ACM

ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return

GSA Capital Partners's PRLD Position: Q2 2026 in Review

GSA Capital Partners opened a new position in Prelude Therapeutics (PRLD) in Q2 2026: 12,672 shares worth $68K. The stake represents ﹤0.01% of the portfolio and ranks #1648 among its holdings. This is a return to the name: GSA Capital Partners previously reported a position in PRLD as recently as Q3 2025.

GSA Capital Partners first reported a position in PRLD in Q1 2022 and has held it in 10 quarters since. The position peaked at $358K in Q3 2022. 75 funds tracked by Wall St. Rank hold PRLD as of Q2 2026.

GSA Capital Partners held 12,672 shares of Prelude Therapeutics worth $68K as of Q2 2026.
Prelude Therapeutics was a new GSA Capital Partners position in Q2 2026.
Prelude Therapeutics made up ﹤0.01% of GSA Capital Partners's portfolio in Q2 2026, its #1648 holding.
GSA Capital Partners first reported a position in Prelude Therapeutics in Q1 2022 and has held it in 10 quarters since.
GSA Capital Partners's Prelude Therapeutics position peaked at $358K in Q3 2022.
75 funds tracked by Wall St. Rank held Prelude Therapeutics as of Q2 2026.

Based on GSA Capital Partners's 13F filing for Q2 2026, filed 6 Aug 2026.